-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Innovation: Professor Li Zifu of Huazhong University of Science and Technology revealed that hyperbaric oxygen can improve the microenvironment of tumor mechanics, promote the delivery of PD-1 antibodies and the infiltration of T cells in tumor sites, and propose a novel immunotherapy for solid tumors with PD-1 antibodies that can be empowered by hyperbaric oxygen.
Strategy
.
Keywords: hyperbaric oxygen therapy, PD-1 antibody immunotherapy, tumor mechanical microenvironment, solid tumor immunotherapy, translational medicine tumor immunotherapy, especially immune checkpoint blocking therapy, has received extensive attention in recent years
.
PD-1/PD-L1 is an important type of immune checkpoint, which is commonly used by tumor cells to induce T cell disability to avoid being cleared by the immune system and causing immune escape
.
The PD-1 antibodies that have been approved for marketing include Merck’s Keytruda, Bristol-Myers Squibb’s Opdivo, Sanofi (Sanofi) and Regeneron (Regeneron) jointly developed Libtayo and Jiangsu Hengrui Medicine’s Camerlizumab
.
However, the clinical application of these PD-1 antibody drugs, like other immune checkpoint blockers, has encountered a huge bottleneck—the overall response rate is low, especially in hepatocellular carcinoma, triple-negative breast cancer, pancreatic ductal adenocarcinoma, etc.
In malignant solid tumors
.
During the occurrence and development of these malignant solid tumors, due to the rapid proliferation of tumor cells, incomplete vascular development, and uneven distribution, the internal oxygen supply is insufficient, resulting in tumor hypoxia and inducing a large amount of HIF-1α expression
.
Tumor hypoxia can further induce tumor development, invasion and metastasis, regulate tumor mechanical microenvironment and immune microenvironment, and severely reduce the responsiveness of tumor tissue to immunotherapy, leading to treatment failure.
Therefore, improving tumor hypoxia is of great significance for enhancing tumor treatment effects.
.
Hyperbaric oxygen therapy (HBO) refers to intermittently giving patients pure oxygen therapy under conditions of higher than normal atmospheric pressure.
It is an effective treatment for improving tissue hypoxia
.
In view of this, this research creatively combined hyperbaric oxygen and immune checkpoint blocker PD-1 antibody for solid tumor immunotherapy, and developed a new strategy for HBO-enabled PD-1 antibody immunotherapy
.
This study verified the effectiveness and safety of hyperbaric oxygen-enhanced PD-1 antibody tumor immunotherapy through multiple models of mouse liver cancer subcutaneous tumors, liver cancer in situ tumors, breast cancer in situ tumors, pancreatic cancer in situ tumors, and liver cancer clinical samples.
Sexuality and universality
.
Combining the transcriptome with a variety of tumor models reveals that hyperbaric oxygen can significantly improve the hypoxia of solid tumors and reduce the content of collagen and fibronectin in the extracellular matrix, thereby effectively improving the mechanical microenvironment of solid tumors and promoting PD-1 antibody in solid tumors It can penetrate and enrich in solid tumors, and improve the infiltration of CD8+ T cells in solid tumors
.
Hyperbaric oxygen combined with PD-1 antibody can improve tumor hypoxia, reduce the amount of bone marrow-derived suppressive cells in the tumor, increase the ratio of M1 type macrophages/M2 type macrophages, and regulate the amount of various cytokines.
The tumor microenvironment changes from immunosuppressive to immunostimulatory
.
It is worth noting that this study not only verified the effectiveness of HBO combined with PD-1 antibody therapy in mice, but also worked with the team of Academician Chen Xiaoping and Professor Zhang Bixiang from Tongji Hospital on tumor tissue samples resected by clinical liver cancer patients.
It is further verified that HBO can enhance the efficacy of PD-1 antibody by improving the mechanics and immune microenvironment of tumor samples
.
More importantly, the cooperative team has applied HBO combined with PD-1 antibody, a new treatment method, for clinical trials and obtained clinical trial ethics approval.
It is currently recruiting patients with advanced liver cancer to carry out clinical trials
.
This research creatively combined HBO and PD-1 antibody, and proposed a new strategy to improve the response of immunotherapy
.
Based on the characteristics of HBO that improves the tumor mechanical microenvironment and promotes the infiltration of lymphocytes in the tumor site, HBO is expected to promote all ACT treatments (adoptive cell therapy), which is also the focus of the team's follow-up research
.
WILEY paper information: Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid TumorsXin Liu, Ningbing Ye, Sha Liu, Jiankun Guan, Qingyuan Deng, Zhijie Zhang, Chen Xiao, Ze-yang Ding, Bi- xiang Zhang, Xiao-ping Chen, Zifu Li*, and Xiangliang Yang Advanced Science DOI: 10.
1002/advs.
202100233 Click "Read the original text" in the lower left corner to view the original text of the paper
.
Introduction to AdvancedScience Journal "Advanced Science" (Advanced Science) Wiley is a high-quality open source journal founded in 2014.
It publishes innovative achievements and cutting-edge progress in various fields such as materials science, physical chemistry, biomedicine, and engineering
.
The journal is dedicated to disseminating scientific research results to the public to the greatest extent, and all articles are freely available
.
The latest impact factor is 15.
840, and the 2020 SCI journals of the Chinese Academy of Sciences will be divided into the Q1 area of the material science category and the Q1 area of the engineering technology category
.
Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
Follow us to share cutting-edge information｜Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com
Strategy
.
Keywords: hyperbaric oxygen therapy, PD-1 antibody immunotherapy, tumor mechanical microenvironment, solid tumor immunotherapy, translational medicine tumor immunotherapy, especially immune checkpoint blocking therapy, has received extensive attention in recent years
.
PD-1/PD-L1 is an important type of immune checkpoint, which is commonly used by tumor cells to induce T cell disability to avoid being cleared by the immune system and causing immune escape
.
The PD-1 antibodies that have been approved for marketing include Merck’s Keytruda, Bristol-Myers Squibb’s Opdivo, Sanofi (Sanofi) and Regeneron (Regeneron) jointly developed Libtayo and Jiangsu Hengrui Medicine’s Camerlizumab
.
However, the clinical application of these PD-1 antibody drugs, like other immune checkpoint blockers, has encountered a huge bottleneck—the overall response rate is low, especially in hepatocellular carcinoma, triple-negative breast cancer, pancreatic ductal adenocarcinoma, etc.
In malignant solid tumors
.
During the occurrence and development of these malignant solid tumors, due to the rapid proliferation of tumor cells, incomplete vascular development, and uneven distribution, the internal oxygen supply is insufficient, resulting in tumor hypoxia and inducing a large amount of HIF-1α expression
.
Tumor hypoxia can further induce tumor development, invasion and metastasis, regulate tumor mechanical microenvironment and immune microenvironment, and severely reduce the responsiveness of tumor tissue to immunotherapy, leading to treatment failure.
Therefore, improving tumor hypoxia is of great significance for enhancing tumor treatment effects.
.
Hyperbaric oxygen therapy (HBO) refers to intermittently giving patients pure oxygen therapy under conditions of higher than normal atmospheric pressure.
It is an effective treatment for improving tissue hypoxia
.
In view of this, this research creatively combined hyperbaric oxygen and immune checkpoint blocker PD-1 antibody for solid tumor immunotherapy, and developed a new strategy for HBO-enabled PD-1 antibody immunotherapy
.
This study verified the effectiveness and safety of hyperbaric oxygen-enhanced PD-1 antibody tumor immunotherapy through multiple models of mouse liver cancer subcutaneous tumors, liver cancer in situ tumors, breast cancer in situ tumors, pancreatic cancer in situ tumors, and liver cancer clinical samples.
Sexuality and universality
.
Combining the transcriptome with a variety of tumor models reveals that hyperbaric oxygen can significantly improve the hypoxia of solid tumors and reduce the content of collagen and fibronectin in the extracellular matrix, thereby effectively improving the mechanical microenvironment of solid tumors and promoting PD-1 antibody in solid tumors It can penetrate and enrich in solid tumors, and improve the infiltration of CD8+ T cells in solid tumors
.
Hyperbaric oxygen combined with PD-1 antibody can improve tumor hypoxia, reduce the amount of bone marrow-derived suppressive cells in the tumor, increase the ratio of M1 type macrophages/M2 type macrophages, and regulate the amount of various cytokines.
The tumor microenvironment changes from immunosuppressive to immunostimulatory
.
It is worth noting that this study not only verified the effectiveness of HBO combined with PD-1 antibody therapy in mice, but also worked with the team of Academician Chen Xiaoping and Professor Zhang Bixiang from Tongji Hospital on tumor tissue samples resected by clinical liver cancer patients.
It is further verified that HBO can enhance the efficacy of PD-1 antibody by improving the mechanics and immune microenvironment of tumor samples
.
More importantly, the cooperative team has applied HBO combined with PD-1 antibody, a new treatment method, for clinical trials and obtained clinical trial ethics approval.
It is currently recruiting patients with advanced liver cancer to carry out clinical trials
.
This research creatively combined HBO and PD-1 antibody, and proposed a new strategy to improve the response of immunotherapy
.
Based on the characteristics of HBO that improves the tumor mechanical microenvironment and promotes the infiltration of lymphocytes in the tumor site, HBO is expected to promote all ACT treatments (adoptive cell therapy), which is also the focus of the team's follow-up research
.
WILEY paper information: Hyperbaric Oxygen Boosts PD-1 Antibody Delivery and T Cell Infiltration for Augmented Immune Responses Against Solid TumorsXin Liu, Ningbing Ye, Sha Liu, Jiankun Guan, Qingyuan Deng, Zhijie Zhang, Chen Xiao, Ze-yang Ding, Bi- xiang Zhang, Xiao-ping Chen, Zifu Li*, and Xiangliang Yang Advanced Science DOI: 10.
1002/advs.
202100233 Click "Read the original text" in the lower left corner to view the original text of the paper
.
Introduction to AdvancedScience Journal "Advanced Science" (Advanced Science) Wiley is a high-quality open source journal founded in 2014.
It publishes innovative achievements and cutting-edge progress in various fields such as materials science, physical chemistry, biomedicine, and engineering
.
The journal is dedicated to disseminating scientific research results to the public to the greatest extent, and all articles are freely available
.
The latest impact factor is 15.
840, and the 2020 SCI journals of the Chinese Academy of Sciences will be divided into the Q1 area of the material science category and the Q1 area of the engineering technology category
.
Press and hold the QR code on the official WeChat platform of AdvancedScienceNewsWiley's scientific research information.
Follow us to share cutting-edge information｜Focus on scientific research trends to publish scientific research news or apply for information sharing, please contact: ASNChina@Wiley.
com
